Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CTL4 | ISIN: CA05455W1086 | Ticker-Symbol: 954
Frankfurt
15.04.24
08:11 Uhr
0,108 Euro
-0,037
-25,52 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AWAKN LIFE SCIENCES CORP Chart 1 Jahr
5-Tage-Chart
AWAKN LIFE SCIENCES CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0770,15515.04.

Aktuelle News zur AWAKN LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.04.Awakn Life Sciences Corp: Awakn launches Awakn Kare licensing deal with Rivus3
03.04.Awakn Life Sciences inks licensing partnership deal with Oklahoma-based clinic1
03.04.Awakn Life Sciences Corp.: Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic173Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted...
► Artikel lesen
13.02.Awakn Life Sciences Corp: Awakn Life Sciences begins trading on CSE3
13.02.Canadian Securities Exchange (CSE): Canadian Securities Exchange Welcomes Listing of Awakn Life Sciences Corp398Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Awakn Life Sciences Corp., a clinical-stage biotechnology...
► Artikel lesen
12.02.CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)263Toronto, Ontario--(Newsfile Corp. - Le 9 février/February 2024) - The common shares of Awakn Life Sciences Corp. have been approved for listing on the CSE. Listing and disclosure documents will...
► Artikel lesen
12.02.Awakn Life Sciences Corp: Awakn Life to begin trading on CSE Feb. 133
05.02.Awakn Life Sciences Corp: Awakn Life delisting review extended2
05.02.Awakn Life Sciences Corp: Awakn to list on CSE, closes $65,714 financing tranche1
05.02.Awakn Life Sciences Corp.: Awakn Life Sciences Announces Conditional Approval of CSE Listing424Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...
► Artikel lesen
24.01.Awakn Life Sciences Corp: Awakn Life completes investigate study on S-ketamine2
24.01.Awakn Life Sciences Corp.: Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers414Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...
► Artikel lesen
21.12.23Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation5
20.12.23Awakn Life Sciences Corp: Awakn licenses S-ketamine formulation from LTS2
20.12.23Awakn Life Sciences Corp.: Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS282Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents Filed in US and Key International MarketsToronto, Ontario--(Newsfile...
► Artikel lesen
15.12.23Awakn Life Sciences Corp: Awakn closes $230,000 fourth tranche of financing3
15.12.23Awakn Life Sciences Corp.: Awakn Life Sciences Provides Corporate Update399Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to...
► Artikel lesen
15.11.23Awakn Life Sciences gets green light for phase III trial in SAUD treatment1
15.11.23Awakn Life Sciences Corp: Awakn receives approvals for phase III AWKN-P001 trial2
15.11.23Awakn Life Sciences Corp.: Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001318AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - November...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1